argenx

argenx Equity

The The Equity of argenx (ARGX.BR) as of Nov 21, 2026 is 8.19 B USD. In the previous year, The Equity was 6.15 B USD — a change of 33.19% (higher).

Equity

8.19 BUSD

YoY

33.19%

Last updated:

In 2025, argenx's equity was 8.19 B USD, a 33.19% increase from the 6.15 B USD equity in the previous year.

The argenx Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
688.96 M USD
Jan 1, 2019
1.32 B USD
Jan 1, 2020
1.87 B USD
Jan 1, 2021
2.83 B USD
Jan 1, 2022
3.15 B USD
Jan 1, 2023
4.58 B USD
Jan 1, 2024
6.15 B USD
Jan 1, 2025
8.19 B USD
The argenx Equity history
YEAREquityYoY
8.19 BUSD+33.19%
6.15 BUSD+34.19%
4.58 BUSD+45.63%
3.15 BUSD+11.03%
2.83 BUSD+51.38%
1.87 BUSD+41.82%
1.32 BUSD+91.66%
688.96 MUSD+48.83%
462.92 MUSD+520.87%
74.56 MUSD+63.54%
45.59 MUSD-33.08%
68.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

argenx Stock analysis

What does argenx do? Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing argenx's Equity

argenx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding argenx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating argenx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

argenx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in argenx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about argenx stock

The Equity of argenx is 8.19 B USD in 2025.

The Equity of argenx changed from 6.15 B USD to 8.19 B USD, representing a 33.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity argenx since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's argenx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — argenx

All Key Metrics — argenx